Capricor Therapeutics, Inc. ( (CAPR) ) has released its Q4 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc. presented to its investors.
Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with a lead product candidate, deramiocel, aimed at treating Duchenne muscular dystrophy cardiomyopathy. The company recently announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical and regulatory endeavors. Key achievements include the FDA’s acceptance of their Biologics License Application for deramiocel, which has been granted priority review with a target action date set for August 31, 2025. Additionally, Capricor reported positive data from its HOPE-2 open label extension trial, showing a 52% slowing of disease progression in patients with Duchenne muscular dystrophy. Financially, Capricor ended 2024 with a cash balance of approximately $152 million, bolstered by a $10 million milestone payment from Nippon Shinyaku and an $80.8 million public offering. Despite reporting a net loss for the year, the company remains financially positioned to support its operations into 2027. Looking ahead, Capricor is focused on advancing deramiocel towards potential commercial launch and expanding its manufacturing capabilities, while also exploring opportunities in exosome-based therapies.